Berberine

Berberine

Best for

Flatten post-meal blood sugar spikes

Likely strong benefit for 12–16 weeks · 6 meta-analyses , n=9.3k

40 papers · 8 claims · 64 outcomes scored · 8 positive

Outcomes

What berberine actually does, by outcome

Each row is one outcome with effect size, evidence base, the dose that worked in trials, and time to first effect. Magnitude tiers come from native-unit MCID where available, Cohen's d otherwise.

Outcome Effect Evidence Dose Weeks Rank
Flatten post-meal blood sugar spikes Likely strong benefit
large
12 meta-analyses n=9.3k Meta-analyzed 0.09–9000 mg 12–16 wk #3/51
Reverse fatty liver buildup Proven strong benefit
large
5 RCTs n=645 500–1500 mg 12–26 wk #1/17
Steady your blood sugar levels Likely benefit
moderate
18 meta-analyses n=15k Meta-analyzed 0.09–9000 mg 6–54 wk #3/109
Improve insulin sensitivity Promising early signal
moderate
9 meta-analyses n=5.3k Meta-analyzed 0.3–9000 mg 8–54 wk #4/78
Lower triglycerides Likely modest benefit
small
18 meta-analyses n=12k Meta-analyzed 0.3–9000 mg 4–54 wk #6/89
Reduce belly and deep abdominal fat Faint early signal
small
7 meta-analyses n=1.9k Meta-analyzed 0.3–1500 mg 12–54 wk
Lose weight on the scale Likely real but unnoticeable
trivial
14 meta-analyses n=5.3k Meta-analyzed 0.3–9000 mg 6–54 wk #5/75
Improve kidney filtration rate Likely real but unnoticeable
trivial
1 meta-analysis n=582 Meta-analyzed 300–9000 mg #2/16

Risk profile

Adverse events and known drug interactions

Safety events

acute cholecystitis (hospitalization, cholecystectomy) severe
acute myocardial infarction severe
bladder cancer severe
retinal hemorrhage severe
abdominal pain moderate
diarrhea mild
constipation mild
flatulence mild

Drug interactions

other major increases concentration
Cyclosporine major increases concentration
Various CYP3A4 Substrates (E.G., Cyclosporine, Indinavir) major increases concentration
Nebivolol major increases concentration
Losartan major increases concentration
Irbesartan major increases concentration
Glipizide major increases concentration
Warfarin major increases toxicity
Olanzapine moderate decreases effect
Simvastatin moderate increases effect

Co-studied with

Supplements that share evidence with berberine

Sources

  1. 1. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. (2015)
  2. 2. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. (2016)
  3. 3. The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. (2020)
  4. 4. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. (2021)
  5. 5. The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial. (2022)
  6. 6. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. (2022)
  7. 7. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study. (2024)
  8. 8. Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research. (2025)
  9. 9. The effects of berberine on depressive symptoms: a systematic review and meta-analysis of preclinical studies. (2025)
  10. 10. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026)

Generated August 14, 2026

Want personalized recommendations?

Show me what works for me